semaglutide april On February 21, 2025, the FDA announced that semaglutide, the active ingredient in Ozempic and Wegovy, is no longer considered in shortage, signaling an improvement in national supply. As a result, compounding How the FDA's Semaglutide Ruling

doi: 10.18632/aging.100276 163 OzorhanUTunaBGCicekdalMBKuskucuABayrakOFYilmazBet al

The potential health benefits are enormous, but so too are the challenges associated with its widespread use

The standard FDAapproved titration schedule for a drug like Semaglutide (Ozempic/Wegovy) starts at 0.25 mg and systematically ramps up to a maximum dose of 2.4 mg

Behavioral interventionsstructured nutrition coaching, strength training, and sleep hygiene optimizationproduce modest but durable weight loss (38% body weight) in motivated individuals, especially when combined with cognitive behavioral therapy for emotional eating